Ovarian cancer is the sixth most common cancer in women, with around 7,500 new cases diagnosed in the UK each year. Currently, only 35% of patients in England will live five years beyond their diagnosis.
Fewer than 1 in 3 patients in England are diagnosed at Stage 1 where survival rates are as good as 95%. The development of screening tools has transformed survival rates for other cancers such as cervical and breast cancer.
Researchers from Prof. Ahmed Ahmed’s group at the MRC Weatherall Institute of Molecular Medicine have used single-cell RNA sequencing to look at the RNA in individual normal cells from the inner layer (epithelium) of Fallopian tubes, which carry eggs from the ovaries to the uterus, and which is the origin of the vast majority of ovarian cancers. By doing so, they were able to identify new subtypes of normal Fallopian tube cells. Surprisingly, the molecular fingerprints of these subtypes were mirrored in individual ovarian cancers. Scientists discovered that single-cell sequencing of the normal Fallopian tube can identify a particular group of ovarian cancer patients who have the poorest chance of surviving the disease and do not benefit from current treatments. Focussing on new treatments for this particular group of patients will be an important way to improve overall survival rates. The research was published in Cancer Cell.
Professor Ahmed Ashour Ahmed, Director of the Ovarian Cancer Cell Laboratory at the MRC Weatherall Institute of Molecular Medicine and Professor of Gynaecology Oncology at the Nuffield Department of Women's and Reproductive Health at Oxford University, said: “Identifying the type of cancer cells is an important early step in choosing which drugs and treatments to use because different types of cells respond differently to treatment. The “Oxford Classic”, our new tumour classifier should give us much more accurate predictions for disease outcome in patients as well as helping us to develop targeted therapies for each type of cancer.”
Zhiyuan Hu, first author on the paper, said: “The discovery of new types of cells sheds new light onto the complexity of ovarian cancers. This research should take us a step closer to identifying the cell of origin of ovarian cancer and to developing a new tool for screening. It also opens the door for similar research for other types of cancers.”
Cary Wakefield, Chief Executive of Ovarian Cancer Action, said: “We fund world-class research to address the low survival rate women diagnosed with ovarian cancer currently face. These exciting findings take us closer to both a screening tool and personalised treatments, the two key elements we know will transform the lives of women diagnosed with ovarian cancer today and for generations to come.”
This project was supported by: